ERBB2 and breast cancer: Over a period of 24 hr, 10 μM NSC624205 killed MDA-MB-468 and SKBR3 cells, which overexpress EGFR and HER2 respectively, but had little effect on the basal-like/triple-negative MDA-MB-231 breast cancer cell line, which does not overexpress either EGFR or HER2 (Figure 1D).